Xenetic Biosciences, Inc. (XBIO)
|52 Week Range||2.4-10.0|
|1y Target Est||-|
|DCF Unlevered||XBIO DCF ->|
|DCF Levered||XBIO LDCF ->|
|Debt / Equity||7.86%||Neutral|
Upgrades & Downgrades
Latest XBIO news
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
16 March 2023
Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 ...
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
5 January 2023
Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
7 September 2022
FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceutical...
2 August 2022
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to tre...
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
18 May 2022
Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical co...
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
8 September 2021
FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T pl...
5 Penny Stocks Analysts Say To Buy With Targets Up To 300%
18 August 2021
Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, New...
Short Squeeze Stocks: NAOV, AHPI and 3 Others Experts Think Are Ready to Pop
16 August 2021
Looking for a list of the best short squeeze stocks available? We've got you covered with Fintel's insight into the topic today.
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
13 August 2021
Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies Strong royalty growth with PolyXen® platform technology Bolstered cash position with recently c...
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >